Axovant to Present Key Intepirdine and Nelotanserin Data at Alzheimer's Association International Conference

BASEL, Switzerland, July 10, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced a number of upcoming presentations relating to its intepirdine and nelotanserin programs at the 2017 Alzheimer's Association International Conference (AAIC) being held in London July 16 – 20.

"This is an exciting time for Axovant and we are pleased to share such a breadth of data relating to our two, late-stage compounds," said David Hung, M.D., chief executive officer of Axovant. "We are committed to advancing the research of and treatment for Alzheimer's disease and Lewy body dementia, as well as other debilitating neurologic diseases for which new treatments are desperately needed."

The following posters will be presented:

Sunday, July 16 2017

Difference in Cognitive Decline between Combination Therapy with Donepezil and Intepirdine (RVT-101) and Donepezil Monotherapy: Results from a 48 Week Multinational Placebo-Controlled Study in Mild to Moderate Alzheimer's Disease
Authors: Marwan Sabbagh, MD, Shankar Ramaswamy, MD, and Harald Hampel, MD, PhD
Time: 9:30 - 10:30 AM
Location: Exhibit Hall
Abstract Number: a15793
Poster Number: P1 - 068

Responder Analysis of the Cognitive Effect of Combination Therapy with Donepezil and Intepirdine (RVT-101) versus Donepezil Monotherapy: Results from a 48 Week Multinational Placebo-Controlled Study in Mild to Moderate Alzheimer's Disease
Authors: Jose Luis Molinuevo, MD, PhD, Shankar Ramaswamy, MD, Ilise Lombardo, MD, and Bote Bruinsma, MD, PhD
Time: 9:30 – 10:30 AM
Location: Exhibit Hall
Abstract Number: a15780
Poster Number: P1 – 058

Dementia with Lewy Bodies is Associated with Greater Dependence: An Autopsy Study
Authors: Yian Gu, PhD, Yaakov Stern, PhD, Shankar Ramaswamy, MD, and James Leverenz, MD
Time: 1:00 – 2:00
Location: Exhibit Hall
Abstract Number: a15580
Poster Number: P1 - 464

Treatment and Resource Utilization Characteristics of Dementia with Lewy Bodies: Analysis of a Large US Administrative Claims Database
Authors: James Leverenz, MD, Griff Vinton, MBA, and Shankar Ramaswamy, MD
Time: 1:00 – 2:00 PM
Location: Exhibit Hall
Abstract Number: a17955
Poster Number: P1 - 591

Monday, July 17, 2017

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Combinations of Donepezil with Glycopyrrolate or Trospium in Elderly Volunteers: The RVT-103 Program
Authors: Shankar Ramaswamy, MD, Stephen Piscitelli, PharmD, Harald Murck, MD, PhD, Dawn Gillmor, BA, and Lawrence Friedhoff, MD, PhD
Time: 9:30 – 10:30 AM
Location: Exhibit Hall
Abstract Number: a15119
Poster Number: P2 - 007

Tuesday, July 18, 2017

HEADWAY-DLB: A Multinational Study Evaluating the Safety and Efficacy of Intepirdine (RVT-101) in Dementia with Lewy Bodies
Authors: Ian McKeith, MD, Dag Aarsland, MD, PhD, Lawrence Friedhoff, MD, PhD, Ilise Lombardo, MD, Nicholas France, MD, Heather Dworak, PhD, Ebenezer Asare, MD, Shankar Ramaswamy, MD, and Brad F Boeve, MD
Time: 9:30 – 10:30 AM
Location: Exhibit Hall
Abstract Number: a15786
Poster Number: P3 - 017

A Summary of Baseline Characteristics from the MINDSET Study: A Global Phase 3 Study of Intepirdine (RVT-101) in Subjects with Mild to Moderate Alzheimer's Disease
Authors: Ilise Lombardo, MD, Geetha Ramaswamy, MD, Ilan Fogel, MD, Yi Mo, PhD, Lawrence Friedhoff, MD, PhD, and Bote Bruinsma, MD, PhD
Time: 9:30 -10:30 AM
Location: Exhibit Hall
Abstract Number: a15653
Poster Number: P3 - 018

Results of a Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Lewy Body Dementia Subjects Experiencing Visual Hallucinations
Authors: Geetha Ramaswamy, MD, Warren Wen, PhD, Lawrence Friedhoff, MD, PhD, and Harald Murck, MD, PhD
Time: 9:30 – 10:30 AM
Location: Exhibit Hall
Abstract Number: a15584
Poster Number:  P3 – 027

Translating Bench Research into Evolving Drug Development: The Case Study of 5HT6 Antagonists
Author: Lawrence Friedhoff, MD, PhD
Time: 9:30 -10:30 AM
Location: Exhibit Hall
Abstract Number: a18773
Poster Number: P3 - 020

Wednesday, July 19, 2017

An Analytical Framework to Project the Potential Medicare Cost Benefit of Intepirdine (RVT-101) in Mild-Moderate Alzheimer's Disease
Authors: Carolyn Zhu, PhD, Ebenezer Asare, MD, Shankar Ramaswamy, MD, Ilise Lombardo, MD, and Yaakov Stern, PhD
Time: 1:00 -2:00 PM
Location: Exhibit Hall
Abstract Number: a20019
Poster Number: P4 - 552

Evaluation of the Neuroprotective Effect of Intepirdine in an in vitro Oxygen/Glucose Deprivation-Induced Cytotoxicity Model
Authors: Ebenezer Asare, MD, Rosemarie Roeloffs, PhD, Brante Sampey, PhD, Shankar Ramaswamy, MD, Bote Bruinsma, MD, PhD, Lawrence Friedhoff, MD, PhD, and Harald Murck, MD, PhD
Time: 1:00 – 2:00 PM
Location: Exhibit Hall
Abstract Number: a20015
Poster Number: P4 - 588

An Analytical Framework for Projecting the Cognitive Effect of Combination Therapy with Intepirdine (RVT-101) and Donepezil versus Placebo after 24 Weeks in Mild-Moderate Alzheimer's Disease
Authors: Steven Rich, MD, James Leverenz, MD, Shankar Ramaswamy, MD, and Harald Hampel, MD, PhD
Time: 9:30 – 10:30 AM
Location: Exhibit Hall
Abstract Number: a15650
Poster Number: P4 - 021

The Dementia Exchange: Conversations and Connections
Axovant also is sponsoring a symposium on Wednesday, July 19 from 6:00 to 9:00 PM BST at the Grange Tower Bridge Hotel featuring world-renowned leaders in dementia research and management:

• Jeffrey Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health
• Harald Hampel, MD, PhD, MSc, Department of Neurology, Pitié-Salpêtrière Medical Center, Sorbonne Universities, Pierre and Marie Curie University
• Alireza Atri, MD, PhD, Ray Dolby Brain Health Center, California Pacific Medical Center
• Marwan Sabbagh, MD, Alzheimer's and Cognitive Disorders Program, Barrow Neurological Institute
• Bengt Winblad, MD, PhD, Karolinska Institute

A keynote will be provided by neuroscientist and best-selling author of Still Alice Lisa Genova, PhD. Pre-registration at http://www.dementiaexchange.com/ is required.

Please visit Axovant at Booth #602 at the ExCel Convention Center.

About Axovant Sciences
Axovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to broadly address multiple forms of dementia and related neurological disorders. Axovant is developing a pipeline of late- and early-stage product candidates that focuses on the cognitive, functional, and behavioral aspects of debilitating conditions such as Alzheimer's disease and Lewy body dementia and other neurological disorders. For more information, visit www.axovant.com.

Forward-Looking Statement
This press release contains forward-looking statements, including statements regarding Axovant's expectations about timing of the results for the Phase 3 MINDSET study of intepirdine in patients with Alzheimer's disease, the Phase 2b HEADWAY-DLB study of intepirdine in patients with DLB, the Phase 2 gait and balance study, DLB and PDD, the Phase 2 study of nelotanserin in patients with LBD suffering from visual hallucinations, the Phase 2 study of nelotanserin in patients with LBD suffering from RBD, the proof of concept and related studies of RVT-103 and RVT-104 in patients with Alzheimer's disease and DLB, and other elements of its clinical development and regulatory strategy.

Forward-looking statements can be identified by the words "believe," "anticipate," "continue", "estimate", "project," "expect," "plan," "potential," "intends," "will," "would", "could", "should" or the negative or plural of these words or other similar expressions that are predictions or indicate future events, trends or prospects.  Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates intepirdine, nelotanserin, RVT-103, and RVT-104; and increased regulatory requirements. These statements are subject to the risk that clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share Axovant's views of the clinical study data. There can be no assurance that the clinical programs for intepirdine, nelotanserin, RVT-103, or RVT-104 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that any of our product candidates will ever receive regulatory approval or be successfully commercialized.

For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Axovant's business in general, see the "Risk Factors" section of our annual report on Form 10-K filed with the Securities and Exchange Commission on June 13, 2017, and other filings that Axovant makes with the SEC from time to time. These forward-looking statements are based on information available to Axovant as of the date of this press release and speak only as of the date of this release. Axovant disclaims any obligation to update these forward-looking statements, except as may be required by law.

SOURCE Axovant Sciences

Related Links

http://www.axovant.com